 Alligator Bioscience Nasdaq Stockholm: ATORX, announces that the company today presents additional novel data from the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer, which further validates the potential of the drug. The presentation will be held at the ASCO American Society of Clinical Oncology Annual Meeting, which this year is being held virtually. 